ES2018903A6 - Un metodo de diagnosticar la presencia de una infeccion virica cronica, como el sindrome de fatiga cronica (cfs) - Google Patents

Un metodo de diagnosticar la presencia de una infeccion virica cronica, como el sindrome de fatiga cronica (cfs)

Info

Publication number
ES2018903A6
ES2018903A6 ES8902387A ES8902387A ES2018903A6 ES 2018903 A6 ES2018903 A6 ES 2018903A6 ES 8902387 A ES8902387 A ES 8902387A ES 8902387 A ES8902387 A ES 8902387A ES 2018903 A6 ES2018903 A6 ES 2018903A6
Authority
ES
Spain
Prior art keywords
chronic fatigue
fatigue syndrome
diagnosing
treating chronic
levels
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES8902387A
Other languages
English (en)
Inventor
William A Carter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hem Research Inc
Original Assignee
Hem Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hem Research Inc filed Critical Hem Research Inc
Publication of ES2018903A6 publication Critical patent/ES2018903A6/es
Priority to ES200301485A priority Critical patent/ES2223273A6/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

METODO DE DIAGNOSTICAR LA PRESENCIA DE UNA INFECCION VIRICA CRONICA, COMO EL SINDROME DE FATIGA CRONICA (CFS). CONSISTE EN DETERMINA LA VIA DE 2''-5'' A/RNASA L, INCLUYENDO LA MEDIDA DE LOS NIVELES DE OLIGONUCLEOTIDOS 2''-5'' A LOS LEUCOCITOS DE LA CIRCULACION SANGUINEA PERIFERICA DEL PACIENTE, Y COMPARAR ESTOS RESULTADOS CON LOS DE INDIVIDUOS SANOS. LA UTILIDAD DEL INVENTO RADICA EN QUE LOS ARN BICATENARIOS, PARTICULARMENTE LOS ARN BICATENARIOS DESAPAREADOS, CUANDO SE ADMINISTRAN EN CANTIDADES APROPIADAS, AUMENTAN EL 2''-5'' A Y NORMALIZAN LA VIA ANTIVIRICA EN PACIENTES CON SINDROME DE FATIGA CRONICA, Y MEJORAN LOS SINTOMAS CLINICOS.
ES8902387A 1988-07-07 1989-07-06 Un metodo de diagnosticar la presencia de una infeccion virica cronica, como el sindrome de fatiga cronica (cfs) Expired - Fee Related ES2018903A6 (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES200301485A ES2223273A6 (es) 1988-07-07 2003-06-24 Mejora de la patente 8902387/0 para un metodo de diagnosticar la presencia de una infeccion virica cronica, como el sindrome de fatiga cronica (cfs).

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22076588A 1988-07-07 1988-07-07

Publications (1)

Publication Number Publication Date
ES2018903A6 true ES2018903A6 (es) 1991-05-16

Family

ID=22824871

Family Applications (2)

Application Number Title Priority Date Filing Date
ES89304188T Expired - Lifetime ES2066847T3 (es) 1988-07-07 1989-04-26 Diagnostico y tratamiento del sindrome de fatiga cronica.
ES8902387A Expired - Fee Related ES2018903A6 (es) 1988-07-07 1989-07-06 Un metodo de diagnosticar la presencia de una infeccion virica cronica, como el sindrome de fatiga cronica (cfs)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES89304188T Expired - Lifetime ES2066847T3 (es) 1988-07-07 1989-04-26 Diagnostico y tratamiento del sindrome de fatiga cronica.

Country Status (13)

Country Link
EP (1) EP0350151B1 (es)
CN (1) CN1056747C (es)
AT (1) ATE103493T1 (es)
AU (2) AU3781189A (es)
CA (1) CA1336685C (es)
DE (1) DE68914201T2 (es)
DK (1) DK332289A (es)
ES (2) ES2066847T3 (es)
IE (1) IE63927B1 (es)
IL (1) IL90875A (es)
NZ (1) NZ229849A (es)
PT (1) PT91094B (es)
ZA (1) ZA895143B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT65370A (en) * 1989-10-16 1994-05-02 Hem Res Inc Diagnosis and treatment of neuro-cognitive disorders associated with systemic immunological malfunction
GB9108085D0 (en) * 1991-04-16 1991-06-05 Scras Complexes of polyadenylic acid with polyuridylic acid
US5776690A (en) * 1996-10-07 1998-07-07 Vojdani; Aristo Detection of chronic fatigue syndrome by decreased levels of RNase L inhibitor mRNA
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
BRPI9908967B1 (pt) 1998-03-20 2017-05-30 Benitec Australia Ltd processos para reprimir, retardar ou de outro modo reduzir a expressão de um gene alvo em uma célula de planta
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
CA2361201A1 (en) 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
US20020132257A1 (en) 2001-01-31 2002-09-19 Tony Giordano Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
EP2405919A4 (en) * 2009-03-13 2013-01-02 Hemispherx Biopharma Inc TREATMENT OF CHRONIC FATIGUE SYNDROME AND EXTENDED QT INTERVAL
WO2019012159A1 (en) * 2017-07-14 2019-01-17 Protea Biopharma N.V. METHODS AND MEANS FOR DIAGNOSING AND / OR TREATING A FATIGUE-ASSOCIATED DISEASE
EP3893893A1 (en) * 2018-12-13 2021-10-20 Aim Immunotech Inc. Methods for improving exercise tolerance in myalgic encephalomyelitis patients

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1326450C (en) * 1985-08-26 1994-01-25 William A. Carter Modulation of aids virus-related events by double stranded rnas (dsrnas)
PH30882A (en) * 1987-03-03 1997-12-23 Hem Res Inc Activated Rnase L as a maker for viral infections.
AU1820388A (en) * 1987-07-17 1989-01-19 Hem Research, Inc. Double stranded rna correction of aberrant metabolic pathways associated with uncontrolled tumor cell and virus growth cycles
ATE122402T1 (de) * 1987-09-04 1995-05-15 Hem Pharma Corp Diagnose von mangelzuständen doppelsträngiger rns.

Also Published As

Publication number Publication date
DK332289A (da) 1990-01-08
PT91094A (pt) 1990-02-08
DK332289D0 (da) 1989-07-04
PT91094B (pt) 1995-01-31
AU3781189A (en) 1990-01-11
EP0350151B1 (en) 1994-03-30
CN1039722A (zh) 1990-02-21
EP0350151A3 (en) 1990-10-03
IE892180L (en) 1990-01-07
ATE103493T1 (de) 1994-04-15
AU6883694A (en) 1994-11-24
CN1056747C (zh) 2000-09-27
ZA895143B (en) 1991-04-24
DE68914201T2 (de) 1994-07-14
DE68914201D1 (de) 1994-05-05
IL90875A (en) 1994-04-12
IL90875A0 (en) 1990-02-09
IE63927B1 (en) 1995-06-28
CA1336685C (en) 1995-08-15
ES2066847T3 (es) 1995-03-16
EP0350151A2 (en) 1990-01-10
NZ229849A (en) 1997-07-27
AU684288B2 (en) 1997-12-11

Similar Documents

Publication Publication Date Title
Shepherd et al. Strategies for reducing coronary heart disease and desirable limits for blood lipid concentrations: guidelines of the British Hyperlipidaemia Association.
Somers et al. Parasympathetic hyperresponsiveness and bradyarrhythmias during apnoea in hypertension
ES2018903A6 (es) Un metodo de diagnosticar la presencia de una infeccion virica cronica, como el sindrome de fatiga cronica (cfs)
Aronne et al. Cardiac autonomic nervous system activity in obese and never‐obese young men
Berman et al. Eating attitudes in seasonal affective disorder and bulimia nervosa
Jung et al. Paroxysmal choreoathetosis: report of Chinese cases
Dawson et al. Diagnostic utility of autonomic measures for major depressive disorders
Hyltander et al. The effect on body composition and exercise performance of home parenteral nutrition when given as adjunct to chemotherapy of testicular carcinoma
Wikby et al. Background, quality of life and metabolic control in patients with insulin-dependent diabetes mellitus
Ventham et al. Childhood leukaemia: a model of pre-obesity
HU9201196D0 (en) Diagnosis and treatment of neuro-cognitive disorders associated with systemic immunological malfunction
Shisslak et al. Typical patterns in atypical anorexia nervosa
Bambery et al. Anorexia nervosa in a patient with systemic lupus erythematosus
Soutou et al. Myeloproliferative disorder therapy: assessment and management of adverse events—a dermatologist's perspective
Llopis THE AXIAL SYNDROME COMMON TO ALL PSYCHOSES: Part 2
Larsson et al. Relaxation training in the treatment of recurrent pediatric headache: The Uppsala studies
Richards Research into aging: exploding myths
Saricam et al. The Coexistence of Obstructive Sleep Apnea in Patients with Slow Coronary Flow: Questionnaire Study
Ehrmann Chapter contents
许以平 et al. RELATIONSHIP BETWEEN IgD AND ASTHMA
Rees An appraisal of the concept of cardiac neurosis
Valine et al. An examination of perceived helplessness in psychiatric patients.
Lukas The Effects of TM on Concurrent Heart Rate, Peripheral Blood Pulse Volume, and the Alpha Wave Frequency.
Mulcahy et al. Timolol, carotid sinus hypersensitivity, and elderly patients
Karnad et al. Diuretic treatment in decompensated cirrhosis and congestive heart failure: effect of posture.

Legal Events

Date Code Title Description
PC1A Transfer granted
FD1A Patent lapsed

Effective date: 20100315